AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 159 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,189,921 | +98.4% | 452,118 | +127.0% | 0.00% | +100.0% |
| Q2 2023 | $5,641,089 | -23.5% | 199,191 | -37.9% | 0.00% | 0.0% |
| Q1 2023 | $7,372,314 | -6.7% | 320,954 | +14.0% | 0.00% | 0.0% |
| Q4 2022 | $7,904,997 | -24.8% | 281,517 | -24.3% | 0.00% | -50.0% |
| Q3 2022 | $10,516,000 | +16.3% | 371,852 | -8.8% | 0.00% | 0.0% |
| Q2 2022 | $9,040,000 | +195.2% | 407,781 | +287.8% | 0.00% | – |
| Q1 2022 | $3,062,000 | +37.9% | 105,163 | +55.7% | 0.00% | – |
| Q4 2021 | $2,220,000 | -62.3% | 67,529 | -47.1% | 0.00% | -100.0% |
| Q3 2021 | $5,893,000 | +190.6% | 127,682 | +247.0% | 0.00% | – |
| Q2 2021 | $2,028,000 | -83.7% | 36,800 | -84.7% | 0.00% | -100.0% |
| Q1 2021 | $12,414,000 | +223.3% | 240,373 | +171.2% | 0.00% | – |
| Q4 2020 | $3,840,000 | -52.1% | 88,622 | -61.3% | 0.00% | -100.0% |
| Q3 2020 | $8,016,000 | +8.2% | 229,031 | +65.4% | 0.00% | 0.0% |
| Q2 2020 | $7,407,000 | -61.9% | 138,499 | -74.7% | 0.00% | -77.8% |
| Q1 2020 | $19,455,000 | +25.5% | 548,341 | +68.9% | 0.01% | +28.6% |
| Q4 2019 | $15,502,000 | +20.8% | 324,673 | -18.0% | 0.01% | +40.0% |
| Q3 2019 | $12,834,000 | -66.8% | 396,102 | -49.0% | 0.01% | -70.6% |
| Q2 2019 | $38,709,000 | +20.3% | 776,058 | +62.7% | 0.02% | +6.2% |
| Q1 2019 | $32,168,000 | +94.2% | 476,988 | +32.8% | 0.02% | +77.8% |
| Q4 2018 | $16,561,000 | -3.7% | 359,135 | +61.1% | 0.01% | +12.5% |
| Q3 2018 | $17,189,000 | +281.4% | 222,890 | +316.6% | 0.01% | +300.0% |
| Q2 2018 | $4,507,000 | -6.8% | 53,501 | -9.6% | 0.00% | -33.3% |
| Q1 2018 | $4,838,000 | -24.3% | 59,155 | -47.1% | 0.00% | -25.0% |
| Q4 2017 | $6,390,000 | +366.8% | 111,770 | +445.2% | 0.00% | +300.0% |
| Q3 2017 | $1,369,000 | -85.0% | 20,500 | -88.4% | 0.00% | -87.5% |
| Q2 2017 | $9,130,000 | +485.6% | 177,453 | +564.6% | 0.01% | +300.0% |
| Q1 2017 | $1,559,000 | -26.7% | 26,700 | -47.6% | 0.00% | 0.0% |
| Q4 2016 | $2,126,000 | -87.0% | 50,966 | -83.5% | 0.00% | -87.5% |
| Q3 2016 | $16,364,000 | +45355.6% | 309,819 | +55027.9% | 0.02% | – |
| Q4 2015 | $36,000 | -99.2% | 562 | -98.5% | 0.00% | -100.0% |
| Q2 2015 | $4,265,000 | +254.2% | 38,374 | +200.5% | 0.00% | +300.0% |
| Q1 2015 | $1,204,000 | -30.8% | 12,771 | -17.8% | 0.00% | -50.0% |
| Q4 2014 | $1,741,000 | -80.1% | 15,537 | -89.1% | 0.00% | -77.8% |
| Q3 2014 | $8,739,000 | +16.2% | 142,452 | -13.2% | 0.01% | 0.0% |
| Q2 2014 | $7,518,000 | – | 164,074 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |